Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620784 · ClinicalTrials.gov registry record · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
A Phase 3 study of BPH and BPH With Urinary Obstruction, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 1
- Study location
NCT05620784 is a Phase 3 study of BPH and BPH With Urinary Obstruction that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 138 participants, above the 43-participant average among 5 other BPH trials with a reported enrollment target (221% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05620784, a Phase 3 study of BPH and BPH With Urinary Obstruction, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .
Conditions Studied
Interventions
- DRUG Furosemide
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05620784
The ClinicalTrials.gov registry entry for NCT05620784 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 43-participant average among 5 other BPH trials with a reported enrollment target (221% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with BPH appearing as the primary indexed condition, and to 1 intervention - of which Furosemide is the first listed.
NCT05620784 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05620784 about?
NCT05620784 is a clinical study titled "Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP". Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to...
What is the current status of trial NCT05620784?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2023-03-01. Estimated completion is 2024-08-01.
What conditions does trial NCT05620784 study?
This clinical trial studies the following conditions: BPH, BPH With Urinary Obstruction, Hematuria, Same Day Discharge.
What interventions are being tested in trial NCT05620784?
The interventions under investigation include: Furosemide (DRUG).
Who is sponsoring clinical trial NCT05620784?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05620784 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BPH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
US Imaging for the Assessment of LUTS
RECRUITING
-
Effect of Group Preoperative Pelvic Floor Training for HoLEP
RECRUITING
-
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
COMPLETED · NA
-
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
COMPLETED · NA
-
LC Bead LUMI for Prostatic Artery Embolization
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.